se of GLP-1 analogs in the treatment of multiple sclerosis - MSGLP

ekárska fakulta UK Bratislava0 个研究点目标入组 50 人开始时间: 2019年9月13日最近更新: 2019年12月16日

试验速览

暂无简介。

•The participant must freely agree to participate in this trial and sign the informed consent by hand prior to performing any procedure in this study.
•A man or woman aged 18 to 60 years (inclusive) at the time of the first study visit.
•Able to understand the requirements and follow the procedures of this study.
•patients with a confirmed diagnosis of multiple sclerosis, with a worse prognosis due to higher disease activity
•Adjustment to stable natalizumab treatment (Tysabri, Elan Pharma International Ltd., Monksland, Athlone, County Westmeath, Ireland).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 50
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•diabetes mellitus on oral antidiabetics or insulin
•other serious chronic diseases
•oncological diseases
•long-term use of medicines such as. glucocorticoids, antidepressants
•pregnancy
•breastfeeding
•drug use or alcohol abuse
•the presence of metal components in the body
•Known hypersensitivity to the test product, excipients, or hypersensitivity to a similar structure.
•Participation in another clinical study during the last 3 months before enrollment or concurrent participation in other clinical studies
•Previous treatment enrollment during this study
•Close connection with the principal examiner (eg a close relative) or the examiner or workplace staff.
•The participant is an employee of the client
•Criteria that, in the examiner's opinion, exclude participation for scientific or safety reasons of the participant.

发起方

ekárska fakulta UK Bratislava